Cardiometabolic Disorders News

People with excess adiposity in young adulthood were more likely to have adverse cardiac structure and function later in life compared with people without it, researchers reported in the European Heart Journal.

GLP-1 receptor agonist use in diabetes and obesity has soared, and indications are now expanding into liver diseases, specifically metabolic dysfunction-associated steatohepatitis. However, the jury is still out on its benefits.

A new drug application for sotagliflozin as an adjunct to insulin therapy for adults with type 1 diabetes and chronic kidney disease has been resubmitted to the FDA, according to a press release.

To put it simply, diabetes and steatotic liver disease are joined at the hip. They are part of the same biological process that involves multiple organs, connected by the concept of metabolic flexibility — or lack thereof.

Metabolic dysfunction-associated steatohepatitis is significantly more common in patients with type 2 diabetes, and most patients with MASH — formerly known as NASH — experience metabolic abnormalities, including obesity.

Metabolic dysfunction-associated steatotic liver disease is a public health threat, affecting 30% to 38% of the adult population globally. The prevalence has risen in parallel with epidemics of obesity and type 2 diabetes.

Millions of dollars have been spent trying to find medications that could treat this complex disorder. The focus has been on drugs for more severe disease, as it leads to complications, and early stages have been somewhat ignored.

Combined SGLT2 inhibitor and GLP-1 receptor agonist therapy could provide additional cardiovascular and renal benefits for adults with type 2 diabetes, according to data from a meta-analysis published in The Lancet Diabetes & Endocrinology.

More than one in five adults in the U.S. with type 1 diabetes also have chronic kidney disease, according to findings from a brief report published in Diabetes Care.

In patients with obesity, gastric bypass surgery plus a very low-energy diet reduced major atherogenic blood lipids to a greater degree than a very low-energy diet alone at 6 weeks, according to the results of the COCKTAIL trial.